Abstract
The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Current Pharmaceutical Biotechnology
Title:Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Volume: 17 Issue: 8
Author(s): Neha N. Parayath, Hayley Nehoff, Sebastien Taurin and Khaled Greish
Affiliation:
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Abstract: The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Export Options
About this article
Cite this article as:
N. Parayath Neha, Nehoff Hayley, Taurin Sebastien and Greish Khaled, Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/1389201017666160401145608
DOI https://dx.doi.org/10.2174/1389201017666160401145608 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design The Development of Cytokine Receptor Antagonists as Potential Therapeutic Agents for the Myeloproliferative Disorders
Current Pharmaceutical Design RAGE and RAGE Ligands in Cancer
Current Molecular Medicine Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Synthesis and Characterization of Fe-Based Metal and Oxide Based Nanoparticles: Discoveries and Research Highlights of Potential Applications in Biology and Medicine
Recent Patents on Nanotechnology Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Cytotoxic and Antitumoral Activity of N-(9H-purin-6-yl) Benzamide Derivatives and Related Water-soluble Prodrugs
Current Molecular Pharmacology Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued) CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Epigenetic Modifications as Therapeutic Targets
Current Drug Targets Chemistry of Potent Anti-Cancer Compounds, Amphidinolides
Current Medicinal Chemistry - Anti-Cancer Agents Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Marine Natural Products with High Anticancer Activities
Current Medicinal Chemistry